MXCT reported Q1 2026 results on May 12 that cleared the revenue bar — yet the stock barely moved, closing at $0.82 and down about 2.4% on the week. That disconnect between an in-line print and a sub-$1 share price captures the central tension here: management is executing to plan, but the market is paying close to nothing for a business with a $100 million SPL milestone pipeline and a royalty stream tied to one of the most watched cell therapies in the world.
The quarter itself was cleaner than the headline numbers suggest. Total revenue came in at $9.7 million — $6.2 million from core and $3.5 million from SPL milestones and royalties, the latter including a $3 million milestone from a partner that dosed patients in a registrational study. Year-on-year comparisons remain ugly in the first half, a hangover from discontinued SPL programs and inventory management by MXCT's largest customer, but management reiterated full-year 2026 guidance of $30 million to $32 million, pointing to core revenue growth in H2 as comparisons ease and the new ExPERT DTx instrument gains traction. Net loss shrank dramatically — from $10.3 million a year ago to $4.75 million — a sign that cost discipline is holding even as revenue drags.
The short-side story is quietly unwinding rather than building. Short interest has fallen about 11% over the past month to roughly 5.2% of free float — still in territory where it is worth watching, but the trend is unambiguously in one direction. The lending market is similarly relaxed: cost to borrow has dropped more than 57% over the past week to just 0.50%, roughly the lowest reading in the past 30 days. Availability in the borrow pool remains wide, suggesting shorts are not scrambling to hold their positions. The ORTEX short score of 50.4 sits at the midpoint of its range with no directional momentum, and days to cover of around 8 days is moderate. The board's announcement of a $10 million share repurchase program — the headline number that emerged from the earnings call — adds a structural bid to the stock at these levels, which may explain part of the short retreat.
The Street view is cautious but not hostile, and some of the recent analyst data warrants a caveat on staleness. Craig-Hallum maintained its Buy rating in late March but cut its target from $7 to $5 — still six times where the stock trades today. Downgrades from BTIG and William Blair in August 2025 moved both firms to the sidelines; those actions are now nine months old and pre-date the Q1 print. The mean price target across the coverage group is $4.11, which is five times the current price — a gap that typically reflects either extreme pessimism already in the stock or targets that have not kept pace with the drawdown. Given the trajectory from $11-$12 targets in 2024 to $5-$6 in early 2026, the latter looks more likely. The factor scores offer a mildly constructive counterpoint: EPS surprise ranks at the 69th percentile and the 12-month forward EPS increase measure scores in the 86th percentile, suggesting estimates have been revised upward even as the stock has not followed.
The one institutional signal worth flagging is from the board itself. Five insiders — the CEO, CFO, chairman, and two directors — bought stock simultaneously in August 2025 at prices between $1.29 and $1.39, collectively deploying roughly $480,000. The CFO then sold a token 10,142 shares in March 2026 at $0.815 — a small, tax-plan-style disposal. The August cluster buy remains the more meaningful data point. Capricorn Fund Managers also initiated a new position of 8.2 million shares as of March 31, becoming the second-largest holder at 7.7% of shares. BlackRock added modestly in the same period. Against that, Cadian Capital trimmed by 4.5 million shares at year-end 2025 and Morgan Stanley cut by 1.25 million — a split between institutional sellers reducing and newer buyers building.
The next catalyst is the H2 revenue trajectory. Management named core revenue growth in the back half of the year as the pivotal test — driven by instrument placements, DTx adoption, and easier year-on-year comparisons. With four SPL programs potentially entering registrational trials in the next 18 months and the FDA's new draft guidance on genome-editing off-target risk expected to structurally increase demand for SeQure assay services, those catalysts are concrete. Whether the stock responds depends less on what the pipeline delivers and more on whether the sub-$1 price itself proves an obstacle to the institutional sponsorship needed to re-rate it.
See the live data behind this article on ORTEX.
Open MXCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
